For instance, the markers of T-cell immunosenescence on peripheral CD8 T cells (measured by the loss of CD28 and presence of CD57 and killer-cell lectin-like receptor (KLRG1) expression) were correlated with worse ORR (p = 0.04), PFS [1.8 vs. 6.4 months, p = 0.009], and OS [2.8 (95% CI, 2.0-NR) vs. 20.8 (95% CI, 6.0-NR) months, p = 0.02] in NSCLC patients (N = 83) treated with ICIs but not in those who underwent PCT (N = 61) [40]. This evidence concerns the gene CD8A and non-small cell lung carcinoma.